ZANVASTRO - (EQ 56MG BASE/2.8ML (EQ 20MG BASE/ML); SOLUTION)

Generic Name	ZILGANERSEN SODIUM	**Innovator**	IONIS PHARMS INC
Dosage	EQ 56MG BASE/2.8ML (EQ 20MG BASE/ML); SOLUTION	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	ZANVASTRO is a glial fibrillary acidic protein (GFAP)-directed antisense oligonucleotide indicated for the treatment of Alexander disease in pediatric and adult patients.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.